Breaking News

Aerie Pharma’s CMO Receives FDA CRL

Was issued in response to CGMP inspection at Tampa facility

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Aerie Pharmaceuticals says it has received notification by its contract drug product manufacturer that the contract manufacturer received a Complete Response Letter (CRL) from the U.S. FDA regarding the contract manufacturer’s New Drug Application (NDA) for one of their own product candidates manufactured at their Tampa, FL facility. According to the contract manufacturer, the CRL refers to a Current Good Manufacturing Practice (CGMP) inspection at the facility. The contract manufacturer has sta...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters